Pay for delay: The Court of Justice of the European Union upholds the judgments of the General Court of the European Union imposing fines on a pharmaceutical company and four generic companies for entering into a deferred entry agreement concerning the antidepressant citalopram (Lundbeck)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. On 25 March 2021, the Court of Justice of the Union delivered its judgment inPay for Delay case C-591/16 (Lundbeck v European Commission)as well as in the five related cases: Sun Pharmaceutical Industries and Ranbaxy (UK)/Commission (C-586/16) Generics (UK) v Commission (C-588/16) Arrow Group and Arrow Generics v Commission (C-601/16) Xellia Pharmaceuticals and Alpharma v Commission (C-611/16) and Merck v Commission (C-614/16). Unsurprisingly, the Court dismisses the appeals against the judgments of the Court of First Instance in those cases and in so doing confirms the fines of almost EUR 150 million imposed by the Commission in its first Pay for Delay